Is there a future for AKT inhibitors in the treatment of cancer?

Valerie M. Jansen; Ingrid A. Mayer; Carlos L. Arteaga

doi:10.1158/1078-0432.CCR-16-0100

Is there a future for AKT inhibitors in the treatment of cancer?

Valerie M. Jansen, Ingrid A. Mayer, Carlos L. Arteaga

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER⁺/HER2^- breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway.

Original language	English (US)
Pages (from-to)	2599-2601
Number of pages	3
Journal	Clinical Cancer Research
Volume	22
Issue number	11
DOIs	https://doi.org/10.1158/1078-0432.CCR-16-0100
State	Published - Jun 1 2016

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-16-0100

Cite this

@article{a99f6c96f38d43a883383cb553c38537,

title = "Is there a future for AKT inhibitors in the treatment of cancer?",

abstract = "An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER+/HER2- breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway.",

author = "Jansen, {Valerie M.} and Mayer, {Ingrid A.} and Arteaga, {Carlos L.}",

note = "Publisher Copyright: {\textcopyright} 2016 American Association for Cancer Research.",

year = "2016",

month = jun,

day = "1",

doi = "10.1158/1078-0432.CCR-16-0100",

language = "English (US)",

volume = "22",

pages = "2599--2601",

journal = "Clinical Cancer Research",

issn = "1078-0432",